Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor R Mirza, Giovanni Scambia, Werner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter

Open source

DOI: 10.1016/s1470-2045(15)00366-6
Published: 2016-01
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-15-00366-6,
  title = {Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial},
  author = {Andreas du Bois and Gunnar Kristensen and Isabelle Ray-Coquard and Alexander Reuss and Sandro Pignata and Nicoletta Colombo and Ursula Denison and Ignace Vergote and Jose M del Campo and Petronella Ottevanger and Martin Heubner and Thomas Minarik and Emmanuel Sevin and Nikolaus de Gregorio and Mariusz Bidziński and Jacobus Pfisterer and Susanne Malander and Felix Hilpert and Mansoor R Mirza and Giovanni Scambia and Werner Meier and Maria O Nicoletto and Line Bjørge and Alain Lortholary and Martin Oliver Sailer and Michael Merger and Philipp Harter},
  year = {2016},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(15)00366-6},
  url = {https://doi.org/10.1016/s1470-2045(15)00366-6}
}

RIS

TY  - JOUR
TI  - Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
AU  - Andreas du Bois
AU  - Gunnar Kristensen
AU  - Isabelle Ray-Coquard
AU  - Alexander Reuss
AU  - Sandro Pignata
AU  - Nicoletta Colombo
AU  - Ursula Denison
AU  - Ignace Vergote
AU  - Jose M del Campo
AU  - Petronella Ottevanger
AU  - Martin Heubner
AU  - Thomas Minarik
AU  - Emmanuel Sevin
AU  - Nikolaus de Gregorio
AU  - Mariusz Bidziński
AU  - Jacobus Pfisterer
AU  - Susanne Malander
AU  - Felix Hilpert
AU  - Mansoor R Mirza
AU  - Giovanni Scambia
AU  - Werner Meier
AU  - Maria O Nicoletto
AU  - Line Bjørge
AU  - Alain Lortholary
AU  - Martin Oliver Sailer
AU  - Michael Merger
AU  - Philipp Harter
PY  - 2016
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(15)00366-6
UR  - https://doi.org/10.1016/s1470-2045(15)00366-6
ER  -

APA

Bois, A. D., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Campo, J. M. D., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., Gregorio, N. D., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. O., Merger, M., & Harter, P. (2016). Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00366-6

Source records

crossref · retrieved 2026-09-26T12:33:18.952Z